In Vitro and Intracellular Activities of Peptide Deformylase Inhibitor GSK1322322 against Legionella pneumophila Isolates | Zendy

Jacques Dubois | Zendy; Maïtée Dubois | Zendy; Jean-François Martel | Zendy; Kelly Aubart | Zendy; Deborah Butler | Zendy

Open Access

In Vitro and Intracellular Activities of Peptide Deformylase Inhibitor GSK1322322 against Legionella pneumophila Isolates

Author(s) -

Jacques Dubois,

Maïtée Dubois,

Jean-François Martel,

Kelly Aubart,

Deborah Butler

Publication year - 2014

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.04006-14

Subject(s) - legionella pneumophila , intracellular , microbiology and biotechnology , in vitro , legionella , extracellular , peptide , legionnaires' disease , biology , pneumonia , antibacterial agent , bacteria , pharmacology , antibiotics , biochemistry , medicine , genetics

GSK1322322, a novel peptide deformylase inhibitor currently in development as an oral and intravenous agent for the treatment of hospitalized community-acquired bacterial pneumonia, showed poorin vitro activity against a panel of 50Legionella pneumophila strains, with MICs ranging from 1 to 16 μg/ml and an MIC90 of 16 μg/ml, but very potent intracellular activity, with the minimum extracellular concentrations capable of inhibiting intracellular proliferation (MIECs) ranging from 0.12 to 2 μg/ml and 98% of the strains being inhibited by concentrations of ≤1 μg/ml.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research